Citations

Clear

75 citation(s) found for "Starlinger, P".

Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid
Taylor, William R., Burger, Kelli N. , Maheshwari, Kalika , Kipp, Benjamin R. , Delgado, Adriana, Streich, Heather M., Cleary, S., Grotz, Travis E., Kendrick, Micheal L., Smoot, Rory L., Starlinger, Patrick P., Thiels, Cornelius A., Truty, Mark J., Warner, Susanne G., Majumder, Shounak, Mills, Krystal , Delgado, Adriana M, Grotz, Travis E , Berger, Calise K. , Taylor, William R. , Mahoney, Douglas W. , Doering, Karen A. , Foote, Patrick H. , Cleary, Sean P. , Grotz, Travis E. , Smoot, Rory L. , Starlinger, Patrick , Thiels, Cornelius A. , Truty, Mark J. , Warner, Susanne G. , Kisiel, John B. , Majumder, Shounak

Mayo Clinic

Journal of Surgical Oncology | June 2, 2026 | Volume: 134 | Issue: 2 | Pages: 257-262

10.1002/jso.70292 | PMID 42226556 Get It

ABSTRACT Background and Objectives Occult intra‐abdominal metastases are identified in approximately 20% of patients with radiographically localized pancreatic ductal adenocarcinoma (PDAC) through staging laparoscopy, as peritoneal cytology is limited in sensitivity. Methylated DNA markers (MDMs) have demonstrated high diagnostic accuracy for PDAC in tumor tissue, blood, and pancreatic secretions. This study assesses the feasibility and diagnostic performance of MDMs in peritoneal lavage fluid collected during staging laparoscopy, comparing their performance to mutant KRAS (m KRAS ) detection. Methods DNA from peritoneal lavage fluid of PDAC patients was analyzed for m KRAS mutations (codons 12, 13, and 61) using droplet‐digital PCR and for 13 MDMs and a reference gene (B3GALT6) using quantitative methylation‐specific PCR. An MDM score was generated from the average signal of the 13 MDMs and evaluated for its ability to detect intra‐abdominal metastases via receiver operator characteristic (ROC) analysis. Results Among 48 patients, 15 (31%) had intra‐abdominal metastases. The MDM score showed 87% sensitivity and 90% specificity (AUC = 0.98), outperforming m KRAS , which showed 40% sensitivity and 85% specificity (AUC = 0.62; p < 0.0001). Conclusions MDMs in peritoneal lavage fluid may enable highly accurate molecular staging of PDAC and warrant validation in larger studies.
Endothelial cell glycogen synthase kinase 3β promotes lipotoxic endotheliopathy and liver inflammation in MASH
Sano, Akitoshi , Guo, Qianqian , Satthawiwat, Nantawat, Hamdi, Asma , Hmaydoosh, Ghefar , 戴新, Yaqoob, Usman , Pavelko, Kevin D. , Miciano, Charlene , Kisseleva, Tatiana , Firdaus, Zeba , Starlinger, Patrick P., Povero, Davide , Ibrahim, Samar H. , Warasnhe, Khaled , Dai, Xin, Ibrahim, Samar H , Pavelko, Kevin D , Guo, Qianqian , Meroueh, Chady , Satthawiwat, Nantawat , Hamdi, Asma, Yaqoob, Usman , Starlinger, P, Pereyra, David , Kostallari, Enis

Mayo Clinic

JCI Insight | May 5, 2026 | Volume: 11 | Issue: 12 | Pages: No page available

10.1172/jci.insight.202552 | PMID 42084928 Get It

In metabolic dysfunction–associated steatohepatitis (MASH), liver sinusoidal endothelial cells (LSECs) acquire a proinflammatory phenotype termed lipotoxic endotheliopathy. We previously identified glycogen synthase kinase 3β (GSK3β) as a central signaling hub in LSECs during MASH. To elucidate the molecular mechanisms and functional outcome of lipotoxicity-induced GSK3β activation in LSECs, we utilized endothelial cell–specific Gsk3 β -KO ( Gsk3 β ΔEnd ) mice fed MASH-inducing diets. Endothelial Gsk3 β deletion significantly reduced markers of lipotoxic endotheliopathy, including adhesion molecules and chemokines, alongside liver injury, inflammation, and fibrosis. Immune profiling via flow cytometry and mass cytometry by time of flight (CyTOF) identified decreased hepatic infiltration of proinflammatory myeloid populations, particularly mature DCs in Gsk3 β ΔEnd mice. In a coculture system, GSK3β in lipotoxic LSECs promoted DCs maturation. Mechanistically, GSK3 inhibition restored lipotoxicity-induced alterations in LSEC mitochondrial morphology and respiration by regulating AMP-activated protein kinase and dynamin-related protein 1. This rescue suppressed chemokine and adhesion molecule expression, thereby limiting immune cell recruitment. Collectively, under lipotoxic stress, GSK3β amplifies mitochondrial dysfunction and inflammatory signaling in LSECs, enhancing myeloid cell homing and DC maturation. Targeting LSEC GSK3β may, therefore, represent a promising therapeutic strategy to mitigate LSEC-driven fibroinflammatory response in human MASH.
CD4+ T cells promote fibrosis during metabolic dysfunction–associated steatohepatitis
Valenzuela-Pérez, Lucía , Bayer, Rachel L., Manna, Dina F., Mishra, Shravan K., Washington, Alexander M. , Hassan, AbidM, Sidahmed, Malaz M., Ssali, Edward, Dinç, Ece Janet , Manwana, Benie K., Ibrahim, Ahmed, Guo, Qianqian, Herman, Adam, Graham, Rondell P., Gores, Gregory J., Starlinger, Patrick, Revelo, Xavier S. , Bamidele, Adebowale O., Hirsova, Petra, Kim Lee, Hyun Se , Hassan, Adna A, Revelo, Xavier , Manna, Dina Faeq , Lee, Hyun Se Kim , Pavelko, Kevin D. , Gores, Gregory J. , Starlinger, Patrick, Ibrahim, Samar H. , Kostallari, Enis , Bamidele, Adebowale O. , Valenzuela-Pérez, Lucía

Mayo Clinic

Hepatology | April 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001772 | PMID 42141897 Get It

Background and Aims: Unresolved inflammation and fibrosis are defining features of metabolic dysfunction–associated steatohepatitis (MASH), a progressive form of steatotic liver disease that can advance to cirrhosis and hepatocellular carcinoma. While innate immune mechanisms in MASH have been extensively characterized, the role of CD4 + T cells remains poorly understood despite their central function in orchestrating immune responses through effector and regulatory mechanisms. Approach and Results: Integrated single-cell proteomic, transcriptomic, and functional analyses were used to investigate the CD4 + T-cell landscape in murine and human MASH. We delineated a profound shift in the differentiation of intrahepatic and peripheral CD4 + T cells toward Th1, regulatory, and cytotoxic phenotypes in murine and human MASH. Notably, hepatic CD4 + T cells exhibited heightened effector activity and elevated secretion of proinflammatory cytokines, thus amplifying inflammatory signaling cascades. The CD4 + T-cell reprogramming in MASH also included the induction of the co-stimulatory receptor OX40. In parallel, OX40 ligand (OX40L)-expressing monocyte-derived macrophages and dendritic cells accumulated in MASH livers, establishing a feed-forward CD4 + T cell-myeloid activation loop. Therapeutic blockade of the OX40–OX40L axis, in turn, reversed liver pathology in mice with established MASH and reduced disease markers in an ex vivo human liver model. Furthermore, genetic depletion or functional inhibition of CD4 + T cells attenuated fibrosis, accompanied by decreased infiltration of monocyte-derived macrophages. Conclusions: These studies provide a comprehensive single-cell proteogenomic atlas of CD4 + T cells in MASH and identify an OX40-dependent CD4 + T cell-macrophage axis as a promising therapeutic target for the treatment of MASH and liver fibrosis.
Toxic lipid-induced epigenetic activation of ICAM1 in liver sinusoidal endothelium regulates myeloid-driven fibro-inflammatory response in MASH
Guo, Qianqian , Satthawiwat, Nantawat, Meroueh, Chady , Hamdi, Asma , 戴新, Warasnhe, Khaled , Washington, Alexander M. , Starlinger, Patrick P., Krivonos, Alex, Cao, Sheng, Jonker, Johan W. , Sluis, Bart van de , Ibrahim, Samar H. , Sano, Akitoshi , Dai, Xin, Jonker, Johan W , van de Sluis, Bart , Ibrahim, Samar H , Meroueh, Chady , Guo, Qianqian , Satthawiwat, Nantawat , Hamdi, Asma, Starlinger, P, Kostallari, Enis , Hamdan, Feda H.

Mayo Clinic

Hepatology | April 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001742 | PMID 41983905 Get It

Background and Aims: Liver sinusoidal endothelial cells (LSECs) acquire a proinflammatory phenotype in metabolic dysfunction–associated steatohepatitis (MASH), characterized by enhanced expression of adhesion molecules and inflammatory mediators, a process termed lipotoxic endotheliopathy. However, the molecular drivers of this transformation remain incompletely defined. Approach and Results: We employed complementary models of lipotoxicity and MASH, including palmitate-treated primary human LSECs (in vitro), cultured precision-cut liver slices (PCLS) from MASH mice and normal human liver treated with MASH-inducing media (ex vivo), and diet-induced MASH models (in vivo). GeoMx digital spatial profiling of human MASH livers revealed enriched proinflammatory and fibrogenic signaling between LSECs and myeloid cells. Among the top upregulated genes and ligand–receptor pairs was ICAM1 , whose expression correlated with disease severity and was increased in human MASH by immunostaining. ATAC-seq on primary mouse LSECs showed enhanced chromatin accessibility at the Icam1 promoter in MASH. Chromatin immunoprecipitation confirmed enrichment of the active epigenetic mark H3K27ac and BRD4 binding at the ICAM1 promoter in human LSECs under lipotoxic stress. Mechanistically, we identified the GSK3β/c-Jun/BRD4 axis as a key regulator of ICAM1 induction in LSECs. In vivo, ICAM1-neutralizing antibody or endothelial-specific epigenetic suppression reduced hepatic inflammation, injury, and fibrosis in MASH mice. Conclusions: ICAM1 is epigenetically upregulated in LSECs during lipotoxic stress and promotes myeloid cell recruitment in MASH. Targeting the epigenetic regulation of ICAM1 may offer a novel therapeutic strategy for treating human MASH.
Liver Metastasectomy in Anal Squamous Cell Carcinoma: The Mayo Clinic Experience
Takacs, Noah , O’Donnell, Conor D. J., Atwell, Thomas D. , Jin, Zhaohui, Jin, Zhaohui , O'Donnell, C. , O'Donnell, Conor D J , Tran, Nguyen , Atwell, Thomas, Jin, Zhaohui , Tran, Nguyen H. , Jethwa, Krishan R. , Starlinger, Patrick

Mayo Clinic

Current Oncology | March 10, 2026 | Volume: 33 | Issue: 3 | Pages: 157

10.3390/curroncol33030157 | PMID 41892185 Get It

Background: Metastatic squamous cell carcinoma of the anus (SCCA) carries a poor prognosis, with systemic therapy remaining the standard of care. While metastasis-directed therapy improves outcomes in select gastrointestinal malignancies, the role of liver-directed intervention in metastatic SCCA remains undefined. We evaluated clinicopathologic features and oncologic outcomes of patients with liver-limited metastatic SCCA treated with curative-intent hepatic local therapy at a tertiary academic center. Methods: We conducted a retrospective cohort study of adults with histologically confirmed SCCA and liver-only metastatic disease who underwent curative-intent hepatic resection or ablation at Mayo Clinic between 1993 and 2023. Patients with extrahepatic disease or incomplete records were excluded. Demographic, tumor, treatment, and outcomes data were abstracted from electronic medical records. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan–Meier method. Prognostic factors were assessed using univariate Cox proportional hazards models. Results: Twenty-five patients met inclusion criteria. Median age was 56.7 years, and 92% were female. Most patients had metachronous metastases (76%), a single hepatic lesion (56%), and unilobar disease (76%). Pre-intervention systemic therapy was administered in 52% of patients, with radiographic complete or partial responses observed in all treated patients. Liver-directed therapy consisted of surgical resection in 80% and thermal ablation in 20%. Among surgical patients, 90% achieved microscopically negative margins. With a median follow-up of 22 months, disease recurrence occurred in 80% of patients, most commonly within the liver. Median DFS was 7.27 months. Median OS from the date of liver-directed therapy was 51.3 months. On univariate analysis, poorly differentiated tumor histology was associated with inferior OS (hazard ratio 4.67, p = 0.018). No other clinicopathologic variables were significantly associated with DFS or OS. Conclusions: In this single-institution experience, carefully selected patients with liver-limited metastatic SCCA undergoing curative-intent hepatic-directed therapy achieved prolonged overall survival, substantially exceeding historical outcomes with systemic therapy alone. Despite frequent recurrence, the observed median OS exceeding four years supports consideration of liver-directed therapy within a multidisciplinary framework for patients demonstrating favorable disease biology and response to systemic treatment. Prospective studies are needed to better define patient selection and optimal integration of local and systemic therapies in the modern treatment era.
Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter?
Tan, Po Hong, Thiels, Cornelius A., Poruk, Katherine E. , Miller, R., Hor, Hoe Yan , Tu, Melody Pi Yin , Huyser, Michelle R., Stucky, Chee-Chee, Wasif, Nabil , Bold, Richard J. , Smoot, R., Starlinger, Patrick P., Warner, Susanne G., Kendrick, M., Stauffer, John A., Truty, M., Fong, Zhi Ven, _, _, Poruk, Katherine, Miller, Richard Max, Thiels, Cornelius A. , Stucky, Chee‐Chee , Starlinger, Patrick , Warner, Susanne G. , Kendrick, Michael L. , Stauffer, John , Truty, Mark J. , Fong, Zhi Ven

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 27-33

10.6004/jnccn.2025.7097 | PMID 41671431 Get It

Background: Upfront resectable pancreatic ductal adenocarcinoma (PDAC) is defined by the NCCN as disease with ≤180° portomesenteric vein (PMV) abutment. However, the clinical significance of PMV abutment in this cohort remains unexplored, and we sought to investigate its impact. Methods: This multi-institutional study included patients who underwent pancreatoduodenectomy (PD) for upfront resectable PDAC from 2002 to 2023. Patients with PDAC with ≤180° PMV abutment were compared with those without. Overall survival (OS) was compared and stratified based on whether patients underwent upfront surgery or neoadjuvant therapy (NAT). Results: Among 1,446 patients included, 521 (36.0%) had PMV abutment. Median OS for patients with PMV abutment was 28.8 months compared with 31.2 months for those without ( P =.17). In a stratified analysis of patients who underwent upfront surgery, patients with PMV abutment had worse OS (19.2 vs 27.6 months; P <.05) and lower R0 resection rates (63.1% vs 87.2%; P <.05) compared with those without. However, in patients who underwent NAT, this difference in R0 resection rate was not observed (91.4% vs 94.0%, respectively; P =.27). Furthermore, there was no significant difference in median OS with NAT (42.5 vs 51.6 months, respectively; P =.48). Conclusions: In this largest cohort to date of patients with upfront resectable PDAC, PMV abutment was associated with worse OS compared with no PMV abutment when an upfront resection strategy was used. The use of NAT in patients with PMV abutment mitigated this survival difference with increased R0 resection rates. These findings suggest that patients with upfront resectable PDAC with PMV abutment benefit from a NAT approach for optimal survival outcomes, and that the current criteria guidelines need to be redefined.
Anatomic subsets of cholangiocarcinoma: More different than alike
Dong, Yawen , Stumpf, Hannah E. , Smoot, Rory L., Starlinger, Patrick P., Yarchoan, Mark , Gores, Gregory J., Ilyas, Sumera, Gores, Gregory J. , Ilyas, Sumera I. , Starlinger, Patrick , Gores, Gregory J. , Starlinger, Patrick , Yarchoan, Mark , Ilyas, Sumera Irie , Dong, Yawen , Smoot, Rory L.

Mayo Clinic

Hepatology | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001672 | PMID 41525598 Get It

Cholangiocarcinoma (CCA) represents a biologically and clinically heterogeneous group of biliary tract malignancies. Growing evidence underscores that the 3 major anatomic subtypes—intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA)—are distinct tumor entities rather than a single disease. Each subtype differs in embryologic origin, carcinogenesis mechanisms, molecular landscape, and immunogenic profile, all of which contribute to variability in diagnosis, treatment responsiveness, and prognosis. The importance of understanding these distinctions is reinforced by the rising global incidence of CCA, which highlights the need for precision medicine approaches based on these subtypes. Recent advances have deepened our insight into subtype-specific risk factors, including chronic biliary diseases and metabolic conditions, while artificial intelligence–driven tools are improving diagnostic accuracy and risk stratification. Surgical innovations now allow for more tailored resections and perioperative care, and therapeutic strategies are increasingly guided by molecular and immune profiling. Emerging strategies for early diagnosis and chemoprevention in high-risk populations further emphasize the significance of recognizing the unique biology of each subtype. In this review, we provide a comprehensive overview of the distinct anatomic subsets of CCA, integrating their molecular and biological foundations with clinical management to inform practice and guide future research.
The E-AHPBA—ESSO—Innsbruck consensus recommendations on peri- and postoperative management following liver resection
Maier, Eva , Stättner, Stefan, Carrión-Álvarez, Lucía , Martino, Marcello Di, Primavesi, Florian, Sochorová, Dana , Laarhoven, Stijn van , Balakrishnan, Anita, Buis, Carlijn I. , Cipriani, Federica, Erdmann, Joris, Frampton, A., Fuks, David, Melloul, Emmanuel, Oberkofler, Christian E. , Petritsch, Stefan, Raab, Helmut, Rahbari, Nuh N. , Rappold, Daniela , Ruzzenente, Andrea, Schäfer, Benedikt , Serrablo, Alejandro, Soreide, Kjetil, Ernesto, Sparrelid, Starlinger, Patrick P, Tinguely, Pascale, Dasari, Bobby V M, Donadon, Matteo, Dopazo, Cristina, Gruenberger, T., Jonas, E G, Malik, Hassan, Siriwardena, Ajith K, Braunwarth, Eva , Di Martino, Marcello , Olthof, Pim , van Laarhoven, Stijn , Cipriani, Federica , Erdmann, Joris I , Lancellotti, Francesco , Oberkofler, Christian , Sallinen, Ville , Søreide, Kjetil , Starlinger, Patrick , Aldrighetti, Luca , Donadon, Matteo , Dopazo, Cristina , Gruenberger, Thomas , Viganó, Luca , Maglione, Manuel , Stättner, Stefan , Primavesi, Florian , Breitkopf, Robert , Fuks, David , Gilg, Stefan , Gulla, Aistė , Margreiter, Christian , Reiberger, Thomas , Ruzzenente, Andrea , Schaefer, Benedikt, Schnitzbauer, Andreas A. , Søreide, Kjetil , Sparrelid, Ernesto , Starlinger, Patrick , Stavrou, Gregor Alexander , Aldrighetti, Luca , Dasari, B. , Gruenberger, Thomas , Jonas, Eduard , Malik, Hassan , Siriwardena, Ajith K. , Maglione, Manuel

Mayo Clinic

British Journal of Surgery | December 30, 2025 | Volume: 113 | Issue: 1 | Pages: No page available

10.1093/bjs/znaf272 | PMID 41467576 Get It

Abstract Background Liver surgery carries a high risk of complications due to the complex interplay of patient-related factors, disease characteristics, and liver function. Expertise is essential for healthcare professionals managing hepatobiliary patients. This European consensus provides evidence-based guidance on selected aspects of peri- and postoperative care. Methods A modified Delphi process was used to achieve consensus, with a 70% agreement threshold. The expert panel comprised hepatobiliary surgeons, anaesthetists, hepatologists, a specialist nurse, and a physiotherapist. A systematic literature search was conducted in PubMed/MEDLINE, Embase, Web of Science, and Cochrane databases. Six topics were addressed: thromboprophylaxis; perioperative antibiotics; prehabilitation/nutrition/mobilization; bile leak including bilioenteric anastomosis leaks; post-hepatectomy haemorrhage; and post-hepatectomy liver failure (PHLF). Evidence appraisal and statement development followed Scottish Intercollegiate Guidelines Network methodology. A patient representative reviewed the guideline. Results Searching the literature yielded 204 included publications from an initial 6514. Thirty-two statements were formulated with a median evidence level of 2. Evidence strength varied by topic with noticeably lower evidence levels in complex surgery settings and less prevalent conditions. In some topics, study heterogeneity and specific inclusion criteria resulted in conditional recommendations, despite high-level evidence. Notably, the weakest evidence was found for perioperative thromboprophylaxis and PHLF management. Strong recommendations were formulated for prehabilitation, early postoperative mobilization, and avoidance of routine drain use. Several evidence gaps warranting multicentre studies were identified. Conclusion Optimizing peri- and postoperative care after liver resection remains challenging. Standardizing key practices and addressing evidence gaps through collaborative research are vital to improve outcomes.
Just right: neutrophils exemplify the Goldilocks principle in liver regeneration
Dong, Yawen , Starlinger, Patrick P, Starlinger, Patrick , Pereyra, David , Dong, Yawen , Starlinger, Patrick , Pereyra, David

Mayo Clinic

Gut | December 24, 2025 | Volume: 75 | Issue: 9 | Pages: 1644-1646

10.1136/gutjnl-2025-337710 | PMID 41443979 Get It

HTK Is a Viable UW Alternative for Hypothermic Oxygenated Machine Perfusion of Liver Grafts Supporting a Single-Solution Protocol
Dingfelder, Jule , Riha, Moriz, Becker, Nikolaus, Rauter, Laurin , Hackl, Hubert , Müller, Julian Flavio, Hammer-Purgstall-Bernd, Felix, Aiad, Monika, Eichelter, Jakob, Starlinger, Patrick P, Silberhumer, Gerd R. , Berlakovich, Gabriela , Györi, Georg, Soliman, Thomas , Starlinger, Patrick , Gyöeri, Georg , Pereyra, David , Becker, Nikolaus , Hackl, Hubert , Eichelter, Jakob , Starlinger, Patrick , Silberhumer, Gerd R , Berlakovich, Gabriela A , Gyoeri, Georg P , Soliman, Thomas , Pereyra, David , Becker, Nikolaus, Salat, Andreas , Györi, Georg

Mayo Clinic

Journal of Clinical Medicine | December 24, 2025 | Volume: 15 | Issue: 1 | Pages: 112

10.3390/jcm15010112 | PMID 41517362 Get It

Background and Aims: Hypothermic oxygenated machine perfusion (HOPE) improves outcomes in orthotopic liver transplantation (OLT), but reliance on University of Wisconsin machine perfusion solution (UW-MPS) increases costs and logistical burden. Histidine-tryptophan-ketoglutarate (HTK) has potential as a single-solution alternative for HOPE. This study evaluated the safety and efficacy of HTK versus UW-MPS during HOPE. Methods: A retrospective, propensity score-matched cohort study including 46 patients who received donation after brain death (DBD) grafts that were preserved with HOPE at the Medical University of Vienna between May 2018 and October 2024 was conducted. A total of 23 patients received grafts perfused with HTK; another 23 patients transplanted with organs perfused with UW-MPS were matched based on recipient age and sodium model of end-stage liver disease score, donor age and sex, cold ischemia time, and perfusion time. Postoperative outcomes, perfusion parameters, and cost differences were assessed. Results: The HTK and UW-MPS cohorts demonstrated comparable perfusion dynamics and vascular resistance. While arterial pressure and flow were higher in the UW-MPS group, clinical outcomes—including early allograft dysfunction (47.8% each), ICU stay, and comprehensive complication index—were statistically similar. A trend toward fewer biliary complications (13.0% vs. 30.4%) and reduced hemodialysis requirement (17.4% vs. 30.4%) was observed in the HTK group. Use of HTK reduced perfusion-related costs by approximately EUR 560 per procedure. Conclusion: HTK is a viable alternative to UW-MPS during HOPE in OLT of DBD grafts, offering comparable short-term outcomes and relevant cost savings. Prospective studies are warranted to validate these findings and explore broader applications of single-solution perfusion strategies.